Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth - Wikidata - awgldk - TriplyDB

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

http://www.wikidata.org/entity/Q34669979

about

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Structural Insights into the Down-regulation of Overexpressed p185her2/neu Protein of Transformed Cells by the Antibody chA21 LPS induces pp60c-src-mediated tyrosine phosphorylation of Hsp90 in lung vascular endothelial cells and mouse lung.Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer Primary trastuzumab resistance: new tricks for an old drug.Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer.Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.Broad targeting of resistance to apoptosis in cancer.An Internal Standard-Assisted Synthesis and Degradation Proteomic Approach Reveals the Potential Linkage between VPS4B Depletion and Activation of Fatty Acid β-Oxidation in Breast Cancer Cells.Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials.Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.Dose-dense chemotherapy for breast cancer: what does the future hold?Biological considerations and clinical applications of new HER2-targeted agents.Treatment of HER2-overexpressing breast cancer.Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?Molecular basis for the actions of Hsp90 inhibitors and cancer therapy.Heat shock protein as molecular targets for breast cancer therapeutics.Heat shock proteins in cancer: targeting the 'chaperones'.Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.P95 HER2 fragments and breast cancer outcome.The Mysterious Ways of ErbB2/HER2 Trafficking

P2860

Q26752780-7418327B-8CB4-45E6-9442-3F7553862F70 Q27022514-48AA89B8-8E35-4D90-8984-F2D887419F64 Q27670462-50B0B204-0C08-40B4-9632-BFCEC0EC5211 Q29347538-3CF155A9-D096-4A6C-8F4F-09490428CFD2 Q34102029-1D707D28-3B09-46DD-BA05-07088AF81C5D Q34165045-47E201FD-661A-453C-BFFB-F9BDB9169050 Q34570753-613AF87C-B10B-4020-A4B3-9ACA8609C27B Q34610251-BECFFAEF-4E83-4192-94F0-A74C9AE232DB Q34664129-2F61EA77-B45F-4CA1-93C4-51026E00D37C Q34852929-F72E283B-C436-4983-9A91-77876D826C31 Q34926558-8ACCA936-4AA5-46EF-BF7A-88D773E22557 Q34938204-0B67D3DF-F5E2-439B-A192-BBB8F0F7E5F7 Q34974436-D0785DE3-2545-4AC1-9053-DE334F170073 Q35098333-0F9736A2-5B64-4481-BD37-1FC16E08B1B1 Q35566217-4FD9BB46-380A-45C9-AD5D-FF46994BDF42 Q35599781-6BEB76F4-0C50-4924-825D-B745D6ADF42C Q35624814-C4844561-B19A-408A-800F-D8180C8558BB Q35625995-A51956D0-DCF6-4D75-B428-6D8C5825F5C5 Q35977527-CE68BE1C-D5F3-45BC-A10A-A3CEA13C3E35 Q36220464-7795E229-0234-4050-870E-950324F6561D Q36269777-C9BD24EA-AA8F-421B-B6D5-CAB8759379CA Q36316817-CA8DB887-A916-4857-BF71-FCF7723E6AED Q36408570-7CBEB250-AD88-4616-9744-222BF29CCD00 Q36465517-C1392EF0-5DBE-463E-BDEB-6512B70F142D Q36483749-0D100389-8ECC-441E-A155-56C105148769 Q36619333-49A0A57D-6629-4D0B-BCAE-48173997A9DF Q37204596-189D23DC-6421-4E85-8DCC-CE2A770A0DA4 Q37332545-44FE9A9A-F1B5-4314-9B9B-552CDC95B76E Q37444430-718DD710-176D-4A6C-801E-2A639C95D371 Q37554911-E98BC636-7488-4D44-A7C1-14FA5CBCBEB7 Q37763100-E0E03B7C-4439-48E0-8738-63B202D2415D Q37788248-F9129578-5B23-4C38-884F-2A67F2E4EB9E Q37799950-B019913E-9446-4581-8811-6597672C25C7 Q37826199-BB67CB9D-CF7C-4879-8F12-05982833FE6A Q37910724-BBCC227C-0F3F-4EF9-8998-9E64DFD5C737 Q37949966-D37C167F-6C15-4A56-A393-33A94F2F6942 Q38008726-936CA385-5825-42FC-892C-7FDBC4D06A16 Q38017732-1B1ED727-4F55-4FF8-AB03-CE461F43CF97 Q38223511-DEE7B1D5-0120-4F5E-B5A5-BC558A393251 Q38237727-C59DF64B-B0CD-47FB-8490-7816EC21065A

P2860

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

http://www.wikidata.org/entity/Q34669979

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Inhibitors of HSP90 block p95- ...... mors and suppress their growth

@ast

Inhibitors of HSP90 block p95- ...... mors and suppress their growth

@en

Inhibitors of HSP90 block p95- ...... mors and suppress their growth

@nl

type

label

Inhibitors of HSP90 block p95- ...... mors and suppress their growth

@ast

Inhibitors of HSP90 block p95- ...... mors and suppress their growth

@en

Inhibitors of HSP90 block p95- ...... mors and suppress their growth

@nl

prefLabel

Inhibitors of HSP90 block p95- ...... mors and suppress their growth

@ast

Inhibitors of HSP90 block p95- ...... mors and suppress their growth

@en

Inhibitors of HSP90 block p95- ...... mors and suppress their growth

@nl

P1433

Q34669979-C58CC010-CE87-4347-9246-581B96823675

P1476

Q34669979-05BEF9CC-34FA-45CA-8686-ECE8D45F8F34

P2093

Q34669979-0DE65C63-9A3E-437C-A1F3-5EA331628C22

Q34669979-15BD30FF-DE81-49AD-BB47-49E1366A51BA

Q34669979-2171DBE7-D024-4E07-948A-6AFE5828F392

Q34669979-2294A2CC-F672-4A26-AFAF-18837A4FD60F

Q34669979-4054F009-D15A-4F95-9324-264226016F9E

Q34669979-4431A42A-9445-46F2-9499-FAAB450B3C7E

Q34669979-8BD43FF9-E4FD-4A78-B4FB-3E137F563CB8

Q34669979-8EB5220F-99BE-49D4-8C65-63C623B1756F

Q34669979-BD9B8DF3-DF80-49E8-B3E0-FFC5BDBD1B5D

P2860

Q34669979-00275D50-6111-4DC2-A0EF-3C4E9D002878

Q34669979-01925F59-840E-4436-A760-F1FC66935E9C

Q34669979-0E76E5FE-0B80-4BFD-9604-29553733277E

Q34669979-13C08A0D-D1C3-4E42-81A2-023D1AB5AA99

Q34669979-2E1A3FE4-35D2-4087-937C-DA421E5B4462

Q34669979-357D584B-236B-4478-B9A3-8A096ED2ABF0

Q34669979-36D62AD3-9C1B-42D1-B5C8-8592AA6AA794

Q34669979-37C84F0C-886C-4967-9EF1-7711B6CB97E3

Q34669979-38033A3E-42F1-45E5-BE32-2FCC9CEB2A47

Q34669979-406ED561-165B-4DED-92AD-F6E8A558BE75

P2888

Q34669979-CDB92E3F-575D-4522-B5C9-18CA6C382C0E

P304

Q34669979-01358AA6-E02A-4196-ABE5-316003843120

P31

Q34669979-DD35B8C4-42AC-4169-9C8F-7616B0310963

P356

Q34669979-317A065B-0413-4CC6-BE7B-8CCCFFEC3FFC

P407

Q34669979-68624E58-AB64-425F-A2F1-1649B06E57CC

P433

Q34669979-2CCE152D-5C26-4F40-B433-737B4E7B9016

P478

Q34669979-08C3140A-D6DB-4BF6-8C68-5003F8AB6426

P50

Q34669979-CD25F00F-0D86-49B1-82C8-5A58E6FB1DD2

Q34669979-E5FAC898-5C23-4D9C-9F53-6A198C388B2E

P577

Q34669979-49B6FF2D-0E96-4E8B-90B4-264DDF73AF44

P5875

Q34669979-DD295A83-D49D-4FAA-A45F-EF528DDFA674

P6179

Q34669979-F3D7F1DF-0A10-48EC-8DF0-54BD24FE24A8

P698

Q34669979-3FDBA191-2CD8-402C-81AD-99B05423E810

P932

Q34669979-63D74E04-845D-487E-AACB-6C6479AE80BA

P356

P1433

P1476

Inhibitors of HSP90 block p95- ...... mors and suppress their growth

@en

P2093

C A Hudis

http://www.w3.org/2001/XMLSchema#string

D B Solit

http://www.w3.org/2001/XMLSchema#string

J Arribas

http://www.w3.org/2001/XMLSchema#string

M Guzman

http://www.w3.org/2001/XMLSchema#string

M Scaltriti

http://www.w3.org/2001/XMLSchema#string

N Rosen

http://www.w3.org/2001/XMLSchema#string

P Angelini

http://www.w3.org/2001/XMLSchema#string

Q Ye

http://www.w3.org/2001/XMLSchema#string

S Chandarlapaty

http://www.w3.org/2001/XMLSchema#string

P2860

Tight control of gene expression in mammalian cells by tetracycline-responsive promoters

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

P2888

P304

325-334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2009.337

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38034847

http://www.w3.org/2001/XMLSchema#string

P6179

1004343185

http://www.w3.org/2001/XMLSchema#string

P698

19855434

http://www.w3.org/2001/XMLSchema#string

P932

3057066

http://www.w3.org/2001/XMLSchema#string